AM841 a covalent cannabinoid ligand powerfully slows gastrointestinal motility in normal and stressed mice in a peripherally restricted manner

摘要

Background and PurposeCannabinoid (CB) ligands have been demonstrated to have utility as novel therapeutic agents for the treatment of pain, metabolic conditions and gastrointestinal (GI) disorders. However, many of these ligands are centrally active, which limits their usefulness. Here, we examine a unique novel covalent CB receptor ligand, AM841, to assess its potential for use in physiological and pathophysiological in vivo studies.